The HAG priming regimen (G-CSF priming combined with low-dose HA chemotherapy) is effective and safe as an induction therapy for patients, including elderly patients, with high-risk MDS and MDS/AML, with CR rates of 46.7%~57.6% in China [8, 9]. The gene discussed is CSF3; the disease is myelodysplastic syndrome.